Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
Kumar, Emil , Korfi, Koorosh , Close, Karina , Leukam, Michael , Ansell, Stephen M. , Scott, Jessica, Clear, Andrew , Siebert, R., Peck, Barrie , Calaminici, Maria , Smith, Sonali M. , Novak, Anne J. , Kumar, Emil Arjun , Ansell, Stephen M , Fitzgibbon, Jude , Okosun, Jessica , Bewicke‐Copley, Findlay , Heward, James A. , Witzig, Thomas E. , Scott, Jessica, Efeyan, Alejo , Green, Michael Richard , Siebert, Reiner, Wang, Jun , Fitzgibbon, Jude

Mayo Clinic

British Journal of Haematology | August 27, 2024 | Volume: 205 | Issue: 5 | Pages: 1804-1809

10.1111/bjh.19671 | PMID 39188028 Get It

SummaryDespite the clinical and molecular heterogeneity of follicular lymphoma (FL), there remains a lack of biomarker‐directed therapeutic approaches in routine clinical practice, with the notable exception of the EZH2 inhibitor tazemetostat in EZH2‐mutant FL. Here we examined whether gene mutation status predicts response to clinical mTOR inhibitors (mTORi) in FL, by performing targeted mutational profiling of biopsies from 21 relapsed/refractory FL patients treated with mTORi everolimus or temsirolimus within clinical trials. We observed an enrichment of mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP in mTORi‐responders, and describe distinct transcriptional characteristics and co‐occurring mutations of FL harbouring these mutations; reinforcing the growing appreciation of CREBBPHAT mutation as a key biological determinant and its promise as a therapeutic biomarker in FL.
Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
Chiang, Chia‐Chun , Schwedt, Todd J. , Dumkrieger, Gina , Chao, Chieh‐Ju , Ouellette, Heather A., Chen, Yi‐Chieh , Burke, Krista M., Wang, Han , Murray, Ann , Montenegro, Monique M. , Stern, Jennifer I. , Whealy, Mark , Cutrer, F. Michael , Chao, Chieh-Ju , Jones, Brandon M, Wang, Han , Murray, Ann M, Cutrer, Fred M, Chiang, Chia-Chun , Schwedt, Todd J , Dumkrieger, Gina , Wang, Liguo , Banerjee, Imon , Jones, Brandon M., Kissoon, Narayan

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 23, 2024 | Volume: 64 | Issue: 9 | Pages: 1094-1108

10.1111/head.14806 | PMID 39176658 Get It

Abstract Objective To develop machine learning models using patient and migraine features that can predict treatment responses to commonly used migraine preventive medications. Background Currently, there is no accurate way to predict response to migraine preventive medications, and the standard trial‐and‐error approach is inefficient. Methods In this cohort study, we analyzed data from the Mayo Clinic Headache database prospectively collected from 2001 to December 2023. Adult patients with migraine completed questionnaires during their initial headache consultation to record detailed clinical features and then at each follow‐up to track preventive medication changes and monthly headache days. We included patients treated with at least one of the following migraine preventive medications: topiramate, beta‐blockers (propranolol, metoprolol, atenolol, nadolol, timolol), tricyclic antidepressants (amitriptyline, nortriptyline), verapamil, gabapentin, onabotulinumtoxinA, and calcitonin gene‐related peptide (CGRP) monoclonal antibodies (mAbs) (erenumab, fremanezumab, galcanezumab, eptinezumab). We pre‐trained a deep neural network, “TabNet,” using 145 variables, then employed TabNet‐embedded data to construct prediction models for each medication to predict binary outcomes (responder vs. non‐responder). A treatment responder was defined as having at least a 30% reduction in monthly headache days from baseline. All model performances were evaluated, and metrics were reported in the held‐out test set (train 85%, test 15%). SHapley Additive exPlanations (SHAP) were conducted to determine variable importance. Results Our final analysis included 4260 patients. The responder rate for each medication ranged from 28.7% to 34.9%, and the mean time to treatment outcome for each medication ranged from 151.3 to 209.5 days. The CGRP mAb prediction model achieved a high area under the receiver operating characteristics curve (AUC) of 0.825 (95% confidence interval [CI] 0.726, 0.920) and an accuracy of 0.80 (95% CI 0.70, 0.88). The AUCs of prediction models for beta‐blockers, tricyclic antidepressants, topiramate, verapamil, gabapentin, and onabotulinumtoxinA were: 0.664 (95% CI 0.579, 0.745), 0.611 (95% CI 0.562, 0.682), 0.605 (95% CI 0.520, 0.688), 0.673 (95% CI 0.569, 0.724), 0.628 (0.533, 0.661), and 0.581 (95% CI 0.550, 0.632), respectively. Baseline monthly headache days, age, body mass index (BMI), duration of migraine attacks, responses to previous medication trials, cranial autonomic symptoms, family history of headache, and migraine attack triggers were among the most important variables across all models. A variable could have different contributions; for example, lower BMI predicts responsiveness to CGRP mAbs and beta‐blockers, while higher BMI predicts responsiveness to onabotulinumtoxinA, topiramate, and gabapentin. Conclusion We developed an accurate prediction model for CGRP mAbs treatment response, leveraging detailed migraine features gathered from a headache questionnaire before starting treatment. Employing the same methods, the model performances for other medications were less impressive, though similar to the machine learning models reported in the literature for other diseases. This may be due to CGRP mAbs being migraine‐specific. Incorporating medical comorbidities, genomic, and imaging factors might enhance the model performance. We demonstrated that migraine characteristics are important in predicting treatment responses and identified the most crucial predictors for each of the seven types of preventive medications. Our results suggest that precision migraine treatment is feasible.
Trends in Transcatheter Aortic Valve Implantation Utilization, Outcomes, and Healthcare Resource Use in Patients With Liver Cirrhosis: A Decade of Insights (2011–2020)
Krittanawong, Chayakrit , Qadeer, Yusuf Kamran , Chen, Bing , Al-Azzam, Fu’ad, Sharma, Samin K. , Jneid, Hani , Wang, Yichen , Wang, Zhen , Alam, Mahboob

Mayo Clinic

Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine | August 23, 2024 | Volume: 23 | Issue: 3 | Pages: 166-173

10.1097/hpc.0000000000000361 | PMID 38598544 Get It

It is well known that individuals with liver cirrhosis are considered at high risk for cardiac surgery, with an increased risk for morbidity and mortality as the liver disease progresses. In the last decade, there have been considerable advances in transcatheter aortic valve implantation (TAVI) as an alternative to surgical aortic valve replacement (SAVR) in individuals deemed to be at high risk for surgery. However, research surrounding TAVI in the setting of liver cirrhosis has not been as widely studied. In this national population-based cohort study, we evaluated the trends of mortality, complications, and healthcare utilization in liver cirrhotic patients undergoing TAVI, as well as analyzed the basic demographics of these individuals. We found that from 2011 to 2020, the amount of TAVI procedures conducted in cirrhotic patients was increasing annually, while mortality, procedural complications, and healthcare utilization trends in these cirrhotic patients undergoing TAVI decreased. Overall, TAVI does seem to be reasonable management for aortic stenosis patients with liver cirrhosis who need aortic valve replacement.
Clinical Outcomes of Cardiogenic Shock Due to Spontaneous Coronary Artery Dissection Versus Cardiogenic Shock Due to Coronary Artery Disease
Krittanawong, Chayakrit , Qadeer, Yusuf Kamran , Sharma, Samin K. , Jneid, Hani , Ang, Song Peng , Wang, Zhen , Alam, Mahboob

Mayo Clinic

Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine | August 23, 2024 | Volume: 23 | Issue: 3 | Pages: 141-148

10.1097/hpc.0000000000000354 | PMID 38467033 Get It

Spontaneous coronary artery dissection (SCAD) can be treated conservatively. However, some SCAD patients can develop cardiogenic shock (CS). We evaluated the outcomes of SCAD-related CS using data from a national population-based cohort study from January 1, 2016, to December 30, 2019. In our study of 32,640 patients with SCAD, about 10.6% of patients presented with CS. We found that SCAD patients with CS had higher mortality and greater complications including use of mechanical circulatory devices, arrhythmias, respiratory support, and acute heart failure compared to those without CS. When comparing CS due to SCAD with that due to coronary artery disease, we found that although mortality rates were similar, those with CS due to SCAD were associated with higher risk of use of mechanical circulatory support, major bleeding, blood transfusion, and respiratory failure.
Longitudinal cardiac magnetic resonance imaging following clinical response to rilonacept and prior to recurrence upon treatment suspension: a RHAPSODY subgroup analysis
Cremer, Paul , Brucato, Antonio , Lin, David , Kwon, Deborah , Jellis, Christine , Clair, JoAnn , Curtis, Allison , Wang, Sheldon, Paolini, John F. , Luis, Sushil A , Jellis, Christine L , Brucato, Antonio , Cremer, Paul C , Insalaco, Antonella , Luis, Sushil Allen , Klein, Allan L. , Imazio, Massimo

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | August 22, 2024 | Volume: 26 | Issue: 1 | Pages: 72-79

10.1093/ehjci/jeae200 | PMID 39172552 Get It

Abstract Aims In the Phase 3 trial, RHAPSODY, rilonacept effectively resolved active pericarditis recurrences, and long-term treatment led to sustained pericarditis recurrence risk reduction. Prior analysis suggested association between higher late gadolinium enhancement (LGE) at baseline and more rapid recurrence upon rilonacept suspension after 12 weeks of treatment. This subgroup analysis assessed the utility of longitudinal serial cardiac magnetic resonance (CMR) imaging for tracking clinical improvement and predicting post-treatment cessation outcomes to help guide clinical decision-making. Methods and results At an 18-month decision milestone (18MDM) in the RHAPSODY long-term extension, investigators decided if patients would continue rilonacept, suspend rilonacept for off-treatment observation, or discontinue the study. Pericardial thickness, pericardial oedema (T2-short tau inversion recovery, T2-STIR), and LGE were determined at baseline and 18MDM by an imaging core lab blinded to clinical data, and pericarditis recurrence was investigator-assessed. CMR results in patients with data at both baseline and 18MDM (n = 13) showed that pericardial thickness, T2-STIR, and LGE were reduced during rilonacept treatment. Among patients with CMR data who suspended rilonacept at the 18MDM (n = 7), five (71%) had a pericarditis recurrence within 1–4 months of rilonacept suspension, despite all having had none/trace LGE (n = 7) and negative T2-STIR (n = 7) at the 18MDM and two having received prophylactic colchicine. Conclusion Continued clinical improvement during prolonged rilonacept treatment corresponded with improvement on CMR, including reduced pericardial thickness, resolution of pericardial oedema, and resolution of LGE. However, none/trace LGE at 18MDM while on treatment did not predict absence of pericarditis recurrence upon subsequent rilonacept suspension in this size-limited subgroup.
Pre-Training Graph Attention Convolution for Brain Structural Imaging Biomarker Analysis and Its Application to Alzheimer’s Disease Pathology Identification
Yang, Zhangsihao , Farazi, Mohammad , Zhu, Wenhui , Chen, Yanxi , Reiman, Eric M. , Caselli, Richard J., Leporé, Natasha , Su, Yi , Rouhi, Rahimeh , Caselli, Richard J. , Chen, Kewei , Wang, Yalin

Mayo Clinic

2024 IEEE International Symposium on Biomedical Imaging (ISBI) | August 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi56570.2024.10635797 Get It

Shifts in Serum Bile Acid Profiles Associated With Barrett's Esophagus and Stages of Progression to Esophageal Adenocarcinoma
Kumar, Aarti , Gwalani, Pranav , Iyer, Prasad G. , Wang, Kenneth K. , Ginsberg, Gregory G. , Lightdale, Charles J. , Portillo, Armando Del , Lagana, Stephen M. , Jin, Zhezhen , Rustgi, Anil K. , Quante, Michael , Falk, Gary W. , Li, Yun , Li, Hongzhe , Genkinger, Jeanine M. , Wang, Timothy C. , Wang, Harris H. , Abrams, Julian A

Mayo Clinic

Clinical and Translational Gastroenterology | August 22, 2024 | Volume: 15 | Issue: 10 | Pages: e1

10.14309/ctg.0000000000000762 | PMID 39166758 Get It

INTRODUCTION: Reflux bile acids are believed to promote esophageal adenocarcinoma (EAC), but the role of systemic bile acids is unknown. This study aimed to assess associations between systemic bile acids and stages of Barrett's esophagus (BE) progression. METHODS: Subjects with and without BE were enrolled in this multicenter cross-sectional study. Targeted serum bile acid profiling was performed, and a subset of subjects completed a validated food frequency questionnaire. RNA sequencing was performed on BE or gastric cardia tissue to assess bile acid associations with gene expression. RESULTS: A total of 141 subjects were enrolled with serum bile acids profiled (49 non-BE; 92 BE: 44 no dysplasia, 25 indefinite/low grade dysplasia, 23 high-grade dysplasia/EAC). Lower Healthy Eating Index score, older age, higher body mass index, and no proton pump inhibitor use were associated with increased levels of multiple bile acids. Global bile acid pools were distinct between non-BE and stages of BE neoplasia ( P = 0.004). Increasing cholic acid was associated with high-grade dysplasia/EAC compared with non-BE, even after adjusting for EAC risk factors (adjusted odds ratio 2.03, 95% confidence interval 1.11–3.71) as was the combination of unconjugated primary bile acids (adjusted odds ratio 1.81, 95% confidence interval 1.04–3.13). High cholic acid levels were associated with tissue gene expression changes including increased DNA replication and reduced lymphocyte differentiation genes. DISCUSSION: Alterations in serum bile acids are independently associated with advanced neoplasia in BE and may contribute to neoplastic progression. Future studies should explore associated gut microbiome changes, proneoplastic effects of bile acids, and whether these bile acids, particularly cholic acid, represent potential biomarkers or viable therapeutic targets for advanced neoplasia in BE.
Specific tension of human muscle in vivo: a systematic review
Persad, Lomas S. , Wang, Zheng , Pino, Paula A. , Binder‐Markey, Benjamin I. , Lieber, Richard L. , Lieber, Richard L , Kaufman, Kenton R.

Mayo Clinic

Journal of Applied Physiology | August 22, 2024 | Volume: 137 | Issue: 4 | Pages: 945-962

10.1152/japplphysiol.00296.2024 | PMID 39169839 Get It

The intrinsic force production capability of human muscle can be expressed as “Specific Tension,” or, the maximum force generated per cross-sectional area of muscle fibers. This value can be used to determine, for example, whether muscle quality changes during exercise, atrophy, disease, or hypertrophy. A value of 22.5 N/cm 2 for mammalian muscle has generally become accepted based on detailed studies of small mammals. Determining the specific tension of human muscle is much more challenging as almost all determinations are indirect. Calculation of human muscle specific tension requires an understanding of that muscle’s contribution to joint torque, its activation magnitude, tendon compliance, and joint moment arm. Determining any of these parameters is technically challenging in humans and thus, it is no surprise that human specific tension values reported vary from 2 to 73 N/cm 2 . In this systematic review, we screened 1,506 published papers and identified the 30 studies published between 1983 and 2023 that used appropriate methods and which reported 96 human specific tension values. We weighted each parameter based on whether it was directly measured, estimated, or calculated based on the literature, with decreasing weighting used, the more indirect the methods. Based on this exhaustive review of the relevant human literature, we suggest that the most accurate value that should be used for human muscle specific tension is 26.8 N/cm 2 .
Deliberations of the Safety Task Force: Risk factors and treatment of adverse events associated with aesthetic injectables
Nikolis, Andreas , Cohen, Joel L. , Enright, Kaitlyn M. , Avelar, Luiz Eduardo Toledo , Beleznay, Katie, Biesman, Brian S. , Cartier, Hugues , Cotofana, Sebastian , Fabi, Sabrina G. , Parada, Meire Brasil, Rzany, Berthold, Wang, Hang, Bromée, Torun, Weiner, Steven C., Avelar, Luiz , Goodman, Greg , Schelke, Leonie , Cotofana, Sebastian , Fitzgerald, Rebecca, Lee, Won , Weiner, Steven

Mayo Clinic

Journal of Cosmetic Dermatology | August 20, 2024 | Volume: 23 | Issue: 11 | Pages: 3551-3564

10.1111/jocd.16476 | PMID 39161297 Get It

AbstractBackgroundThe growing popularity of aesthetic procedures involving fillers, biostimulators, and neurotoxins has prompted concerns about patient safety. To address these concerns, a global Safety Task Force (STF) was formed.AimsThe inaugural STF meeting prioritized vascular compromise prevention and management, guiding clinical trial design and materials for future meetings, and collecting data from experts on current safety methods.MethodsThe STF was formed and consisted of 16 experts from nine different countries, with each possessing distinct expertise in various fields related to aesthetic injectables. Current safety data, protocols, knowledge gaps and future research priorities were discussed and voted upon.ResultsThe establishment of a global database for tracking filler‐related AEs was favored by 93% of participants. Discussions revolved around the database's scope, data standardization, and whether non‐medical contributors should be included. Aspiration as a safety technique garnered support from 73% of participants. Approximately 43% of participants incorporate ultrasound in their injections, with divergent opinions on its impact and potential when used as a standard of practice versus in AE management. Most physicians on the task force incorporated cannula use for some of their injections (93%). There were varying perspectives on treatments for vascular adverse events (VAE), the primary causes, and the adoption of new protocols in the field.ConclusionsThe STF meeting underscored the need for a coordinated effort to address complications related to HA fillers, including VAE management and hyaluronidase protocols. Reliable treatment endpoints were evaluated, but improved measurement methods are needed. Future meetings will focus on addressing delayed complications, furthering safety in this field.
Epigenome‐wide association study of prostate cancer in African American men identified differentially methylated genes
Berglund, Anders , Yamoah, Kosj , Falahat, Rana , Kim, Sungjune, Dutil, Julie , Ruiz-Deyá, Gilberto, Sanchez, Carmen Ortiz, Park, Hyun, Banerjee, Hirendra N., Lotan, Tamara, Barry, Kathryn Hughes , Putney, Ryan M. , Kim, Young‐Chul , Chakrabarti, Ratna , Eschrich, Steven A , Kim, Seung Joon , Park, Jong Y , Yamoah, Kosj , Berglund, Anders E , Mulé, James J. , Matta, Jaime L. , Wang, Liang , Banerjee, Hirendra N., Gwede, Clement K. , Kresovich, Jacob K. , Kim, Youngchul, Lin, Hui‐Yi , Dhillon, Jasreman , Park, Jong Y.

Mayo Clinic

Cancer Medicine | August 20, 2024 | Volume: 13 | Issue: 16 | Pages: No page available

10.1002/cam4.70044 | PMID 39162297 Get It

Abstract Introduction Men with African ancestry have the highest incidence and mortality rates of prostate cancer (PCa) worldwide. Methods This study aimed to identify differentially methylated genes between tumor vs. adjacent normal and aggressive vs. indolent PCa in 121 African American patients. Epigenome‐wide DNA methylation patterns in tumor DNA were assessed using the human Illumina Methylation EPIC V1 array. Results Around 5,139 differentially methylated CpG‐sites (q < 0.01, lΔβl > 0.2) were identified when comparing normal vs. tumor, with an overall trend of hypermethylation in prostate tumors. Multiple representative differentially methylated regions (DMRs), including immune‐related genes, such as CD40 , Galectin3 , OX40L , and STING , were detected in prostate tumors when compared to adjacent normal tissues. Based on an epigenetic clock model, we observed that tumors’ total number of stem cell divisions and the stem cell division rate were significantly higher than adjacent normal tissues. Regarding PCa aggressiveness, 2,061 differentially methylated CpG‐sites (q < 0.05, lΔβl > .05) were identified when the grade group (GG)1 was compared with GG4/5. Among these 2,061 CpG sites, 155 probes were consistently significant in more than one comparison. Among these genes, several immune system genes, such as COL18A1 , S100A2 , ITGA4 , HLA‐C , and ADCYAP1 , have previously been linked to tumor progression in PCa. Conclusion Several differentially methylated genes involved in immune‐oncologic pathways associated with disease risk or aggressiveness were identified. In addition, 261 African American‐specific differentially methylated genes related to the risk of PCa were identified. These results can shedlight on potential mechanisms contributing to PCa disparities in the African American Population.